US EditionThree Million Euros for a Drug – New Products Drive Drug Spending
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
The expenditures of the statutory health insurance companies for medications rise strongly. The reason are new, patent-protected preparations, which often have no added value for the patients. According to the insurance companies, the price regulation has to be reformed.
Kremmen – The financial situation of the statutory health insurance (GKV) system remains strained. The GKV umbrella association clarified this today in Kremmen, Brandenburg. Following a significant increase in supplementary contributions at the beginning of the year, there have already been eight further increases by May, said Doris Pfeiffer, head of the GKV umbrella association.
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
